TG THERAPEUTICS, INC. (TGTX)
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
Address
2 GANSEVOORT STREET, 9TH FLOOR
NEW YORK, NY 10014
Founded
1993
Number of Employees
264
Website
http://www.tgtherapeutics.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)